Author:
Dronca Roxana,Kumar Anagha Bangalore
Publisher
Springer International Publishing
Reference52 articles.
1. Alexandroff, A. B., Jackson, A. M., O’Donnell, M. A., & James, K. (1999). BCG immunotherapy of bladder cancer: 20 years on. Lancet, 353, 1689–1694.
2. Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., Safran, H., Stinchcombe, T. E., Srdanov, M., Gelb, A. B., Schlichting, M., Chin, K., & Gulley, J. L. (2017). Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. Journal of Clinical Oncology, 35, 2117–2124.
3. Aron, M., Nguyen, M. M., Stein, R. J., & Gill, I. S. (2008). Impact of gender in renal cell carcinoma: An analysis of the SEER database. European Urology, 54, 133–140.
4. Atkins, M. B., Plimack, E. R., Puzanov, I., et al. (2016). Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results. Annals of Oncology, 6, 266, abstract 773PD.
5. Atkins, M. B., McDermott, D. F., Powles, T., et al. (2017). IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun) (abstract 4505). 2017 American Society of Clinical Oncology annual meeting.